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Abstract 
 
The gastric peptide hormone human PYY3-36 is a target for the development of 
therapeutics, especially for treatment of obesity. The conformation and aggregation 
behaviour of PEGylated and lipidated derivatives of this peptide is examined using a 
combination of fluorescence dye assays, circular dichroism (CD) spectroscopy, 
analytical ultracentrifugation (AUC) measurements, small-angle x-ray scattering 
(SAXS) and cryogenic-transmission electron microscopy (cryo-TEM). The behaviour 
of two PYY3-36 derivatives lipidated (with octyl chains) in different positions is 
compared to that of two derivatives with PEG attached at different residues and to that 
of the native peptide. We find that, unexpectedly, PYY3-36 forms amyloid fibril 
structures above a critical aggregation concentration. Formation of these structures is 
suppressed by PEGylation or lipidation. PEGylation significantly reduces the 
(reversible) loss of -helix content observed on heating PYY3-36. The PEG conjugates 
form mainly monomeric structures in solution, coiled coil formation and other 
aggregation presumably being sterically hindered by swollen PEG chains. However, 
some small aggregates are detected by AUC. In complete contrast, both of the two 
lipidated peptides show the formation of spherical micelle-like structures which are 
small oligomeric aggregates. Our findings show that PEGylation and lipidation are 
complementary strategies to tune the conformation and aggregation of the important 
gastric peptide hormone human PYY3-36. 
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Introduction 
 
Obesity is fast emerging as a global healthcare issue and this has stimulated research to 
understand the condition and ultimately to develop treatments. A key area of interest 
concerns peptide hormones, a series of which are involved in appetite stimulation or 
suppression.1 These peptide hormones are secreted from organs including the pancreas, 
stomach and intestine. 
The Neuropeptide Y (NPY) family of peptide hormones are secreted in the gut and are 
involved in several processes involved with the feeling of satiety following feeding.2 
These neuropeptides serve as ligands for G-protein coupled Y receptors. The NPY 
family includes peptide YY (PYY), NPY and pancreatic peptide (PP).3-4 Here, we 
investigate derivatives of the human PYY3-36 peptide. This peptide is a gut hormone 
released by the L cells of the gastrointestinal tract following food intake and it is 
produced from the endogenous precursor PYY1-36 peptide via rapid hydrolysis to the 34 
amino acid peptide, PYY3-36, by the peptidase enzyme DPP4 which removes the first 
two amino acids, tyrosine and proline, at the N-terminus.5 This alters the receptor 
selectivity and as a result PYY3-36 has a high selectivity for the Y2 receptor, compared 
to PYY1-36 which has selectivity for the Y1, Y2, and Y5 receptors.
6  The sequence of 
PYY3-36 is shown in Scheme 1a which also shows the lipidated and PEGylated 
derivatives studied in this paper. Solution NMR studies have established that PYY3-36 
adopts a partially -helical structure in aqueous solution.7-8 Residues from L(17) to 
T(32) are believed to lie in the -helical domain as shown in red in Scheme 1b. The 
helical wheel representation of the alpha helix of PYY3-36 (Scheme 1c) suggests a 
possible tendency for facial segregation of charged residues (bottom right) and 
uncharged residues (top left). 
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In the present manuscript, we investigate the effect of PEGylation and lipidation on the 
conformation and aggregation of derivatives of PYY. The conformation is probed using 
circular dichroism (CD) spectroscopy. This technique also provides some information 
on aggregation, however this is examined with less ambiguity via analytical 
ultracentrifugation. Potential self-assembly is investigated using a powerful 
combination of cryogenic-transmission electron microscopy (cryo-TEM) and in situ 
small-angle X-ray scattering (SAXS). PEGylation of PYY3-36 leads to extended 
circulation half-life, although its activity in inhibiting food intake was found to be  
eliminated (in a mouse model).9 However, attachment of PEG via a hydrolysable linker 
restored this activity.9  In another study, palmitoylated PYY3-36 derivatives were 
reported to show self-assembly behaviour (into nanotape or micellar structures 
depending on pH).10 Here, we show that the octyl lipid derivatization suppresses the 
fibrillisation observed for PYY3-36 itself and instead stabilizes the formation of micelles. 
We also demonstrate that PEGylation leads to the formation of PEG-stabilized 
monomers, i.e. the PEG is shown to have a valuable role in preventing self-assembly.   
This paper complements a recent manuscript on the conformation and self-assembly of 
several PYY peptides substituted with lysine bearing -glutamyl linked palmitoyl lipid 
chains at S(13), R(19) or R(25).10  In the current paper, lipidation involves substitution 
of L(17) or Y(21) with octyl-bearing lysine derivatives or substitution of lysine 
derivatives bearing short PEG oligomers. Both of these sites have been chosen to lie 
within the -helical domain (Scheme 1b). Based on a complete alanine scan of 
neuropeptide Y, a close homologue of PYY activating the same receptors, binding to 
the human Y2 receptor (a receptor for pancreatic peptide hormones) only depends on 
residue 5 and final C-terminus sequence. Hence, positions 17 and 21 were chosen as 
they lie in the centre of the molecule at one face of the alpha-helix and can freely be 
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substituted and modified without obstructing the peptide activity at the human Y2 
receptor.11 The conformation of PYY3-36 has been determined from solution NMR 
studies. Scheme 2a shows an ensemble of conformers obtained from one of these 
studies (published as pdb file 2dez).12  
 
There have been few other prior studies on PYY peptide derivatives. One investigation 
of conjugation of Vitamin B21 to PYY3-36 which has been shown to lead to improved 
function, in particular reduced food intake in a rat model.13 An NMR-based structure 
of the conjugate, used as a constraint in molecular dynamics simulation modelling, was 
also published.14  
 
Improving the chemical and physical stability of peptides for applications as therapeutic 
agents is an important research challenge.15-16 Strategies include conjugation of lipid 
and polymer chains. A commonly used polymer for such applications is polyethylene 
glycol (PEG), attachment of which is termed PEGylation. PEGylation is a well-known 
strategy to improve the stability of proteins and peptides in vivo, 17-23 as a result of  so-
called steric stabilization, and this action was confirmed for a human PP (hPP) 
derivative (PEGylated at lysine residue 22).24  This was also shown to reduce food 
intake in mice.24 It has been shown that PEGylation (N-terminal or N- and C-terminal) 
stabilizes the conformation of de novo designed coiled coil forming peptides against 
changes in concentration and temperature.25-26  
 
Lipidation is another strategy employed to improve the biostability of peptides for 
therapeutic applications and it enhances compatibility of the molecule with lipid 
membranes and facilitates extended circulation via binding to serum albumin.27-29 In 
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one study on a lipidated NPY family peptide, Bellman-Sickert et al. showed that 
lipidation improved the pharmacokinetic properties of hPP and prolonged the reduction 
of food consumption in a mouse model.29 The lipidated peptide showed a greater 
resistance to degradation and excretion than PEG analogues which were also prepared 
and investigated. 
 
 
Experimental 
Synthesis. Peptides were synthesized as described previously.30 Briefly, peptide 
sequences were built up using solid phase peptide synthesis on a Rink amide resin. For 
PEGylation, N-termini as well as Lys side chains that were not intended to be 
PEGylated were blocked by the UV-cleavable 6-nitroveratryloxycarbonyl (Nvoc) 
protection group. Peptides were cleaved from the resin and reacted in solution with 
MeO-PEG-NHS with an average molecular weight of 22 kDa in the presence of 4-
dimethylaminopyridine in DMF. Afterwards, the Nvoc protection group was cleaved. 
For lipidation, Lys side chains were protected using the N-(1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)ethyl) (Dde) group. The N-terminus was tert-butyloxycarbonyl 
(Boc) protected. After selective deprotection of Lys with hydrazine, the γ-L-glutamoyl 
linker was introduced the following way: Fmoc-L-Glu-OtBu was coupled via the γ-
carboxy group of the glutamoyl side chain using carboxyacid activation with N,N-
diisopropylcarbodiamide (DIC) and hydroxybenzotriazole (HOBT), followed by 
cleavage of fluorenylmethoxycarbonyl (Fmoc) and coupling of octanoic acid using the 
same activation technique. After cleavage from the resin, all peptides were purified by 
reversed phase high performance liquid chromatography. Identity was proven by matrix 
assisted laser desorption/ionization time of flight mass spectrometry.  The attached PEG 
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has a molar mass of 22271 Da  (MeO-PEG-NHS 20000 Da from Iris Biotech GmbH) 
and a dispersity D= 1.04. Molecular weights were 4047.07 g/mol (PYY3-36), 4317.23 
g/mol (K17-Eoct), 4267.25 g/mol (K21-Eoct), ~24,000 g/mol (K17-PEG22) and 26267 
g/mol (K21-PEG22) determined by mass spectrometry using an Ultraflex III Maldi-
TOF/TOF (Bruker Daltonics, Bremen, Germany). 
Sample Preparation. For circular dichroism (CD), cryo-transmission microscopy 
(cryo-TEM), small angle X-ray scattering (SAXS) and automatic ultracentrifugation 
(AUC) studies, weighed amounts of peptide powder and water were left to equilibrate 
at the desired wt % concentration of peptide. For ANS and ThT assays, the peptides 
were dissolved in a stock solution containing the corresponding fluorophore.  
Fluorescence Spectroscopy. 8-anilo-1-naphthalenesulfonic acid (ANS) and 
Thioflavin T (ThT) were used to locate the critical aggregation concentration (cac). The 
ANS fluorophore is sensitive to the hydrophobicity of its surrounding environment,31 
making it suitable to determine the cac due to hydrophobic collapse.  ThT fluorescence 
binds to amyloid-like structures32-33 (-sheet fibrils) and is used to detect the cac due to 
amyloid formation.  Samples for ANS or ThT assays were prepared by dilution in 2x10-
3 wt% ANS or 5x10-3 wt% ThT of a mother sample prepared as 0.2 wt% peptide in 
2x10-3 wt% ANS or 5x10-3 wt% ThT. 
Spectra were recorded with a Varian Cary Eclipse Fluorescence Spectrometer with 
samples in 4 mm inner width Quartz cuvettes. 
ANS assays were performed measuring spectra from 400 to 670 nm (ex = 356 nm), 
while ThT assays were performed measuring spectra from 460 to 600 nm (ex = 440 
nm).  
 Results from the ANS or ThT assays are plotted as I/I0 vs c or vs log(c) (I: fluorescence 
intensity of peptide dissolved in 2x10-3 wt% ANS or 5x10-3 wt% ThT; I0: fluorescence 
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intensity of 2x10-3 wt% ANS or 5x10-3 wt% ThT; em: emission wavelength, c: peptide 
concentration). 
Analytical Ultracentrifugation (AUC). For characterisation of the peptide solutions, 
sedimentation velocity scans were recorded for a dilution series, starting from 0.1 wt% 
conjugated peptide. All experiments were performed at 55000 rpm, using a Beckman 
XLI analytical ultracentrifuge with an An-60Ti rotor at 20˚C. Data were recorded using 
the absorbance (at 280 nm) and interference optical detection systems. The density and 
viscosity of the water was measured experimentally using a DMA 5000M densitometer 
equipped with a Lovis 200ME viscometer module. The partial specific volume of the 
peptide was calculated using SEDFIT from the amino acid sequence. The partial 
specific volume of PEG was taken as 0.825 mL/g,34 and that of the lipid was calculated 
using the method of Durchschlag and Zipper.35   
The theoretical apparent partial specific volumes (?̅?𝑇) of the conjugated peptides were 
calculated according to: 
                         ?̅?𝑇 =
(𝑀𝑃 ?̅?𝑃)+(𝑀𝐶 ?̅?𝐶)
(𝑀𝑃+𝑀𝐶)
                                         (1) 
Where 𝑀𝑃 and ?̅?𝑃 denote the molecular mass and partial specific volume of the peptide, 
respectively, and 𝑀𝐶 and ?̅?𝐶 denote the molecular mass and partial specific volume of 
the conjugate, respectively. Data were processed using SEDFIT, fitting to the c(s) 
model.36 
Circular Dichroism (CD) Spectroscopy. CD spectra were recorded using a Chirascan 
spectropolarimeter (Applied Photophysics, UK). Peptide solutions were placed in a 
quartz bottle (1 mm path length). Spectra were measured with a 0.5 nm step, 1 nm 
bandwidth, and 1 s collection time per step. The CD signal from the water background 
was subtracted from the CD data of the sample solutions. Temperature was manually 
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changed, while the sample was left to equilibrate for 3 minutes after the assigned 
temperature has been reached, before collecting the CD data.  
Ellipticity is reported as the mean residue ellipticity ([], in deg cm2 dmol-1) and 
calculated as: 
[] = []𝑜𝑏𝑠
MRW
10 𝑐 𝑙 
                        (2) 
[]𝑜𝑏𝑠 is the ellipticity measured in millidegrees, MRW is the mean residue molecular 
weight of the peptide (molecular weight divided by the number of amino acid residues 
= 34, Scheme 1), c is the total concentration in mg/ml, and l is the optical path length 
of the cell in centimeters.  
CD spectra were dominated by an -helical secondary structure. The -helix content, 
f, is calculated as:37  
𝑓 = 100 []222/[]222
𝑒𝑥                      (3) 
 []222
𝑒𝑥  in Equation 3 is the extrapolated value for the molar ellipticity: 
[]222
𝑒𝑥 = [](1 −
𝑘
𝑛
)       (4) 
where []222
𝑒𝑥 = -31556 deg cm2 dmol-1,  [] = -37400 deg cm2 dmol-1 is the maximum 
mean residue ellipticity at 222 nm of a peptide with infinite length and 100% helix 
content,37 n= 16 is the number of residues/helix (Scheme 1b) and k is a wavelength-
dependent constant (2.5 at 222 nm).  
Cryogenic-Transmission Electron Microscopy (Cryo-TEM). Imaging was carried 
out using a field emission cryo-electron microscope (JEOL JEM-3200FSC), operating 
at 200 kV. Images were taken in bright field mode and using zero loss energy filtering 
(omega type) with a slit width of 20 eV. Micrographs were recorded using a Gatan 
Ultrascan 4000 CCD camera. The specimen temperature was maintained at -187 oC 
during the imaging. Vitrified specimens were prepared using an automated FEI 
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Vitrobot device using Quantifoil 3.5/1 holey carbon copper grids with a hole size of 3.5 
m. Just prior to use, grids were plasma cleaned using a Gatan Solarus 9500 plasma 
cleaner and then transferred into the environmental chamber of a FEI Vitrobot at room 
temperature and 100 % humidity. Thereafter 3 ml of sample solution was applied on 
the grid and it was blotted twice for 5 seconds and then vitrified in a 1/1 mixture of 
liquid ethane and propane at temperature of -180 °C. The grids with vitrified sample 
solution were maintained at liquid nitrogen temperature and then cryo-transferred to the 
microscope. 
Small-Angle and X-Ray Scattering (SAXS). Synchrotron SAXS experiments on 
solutions were performed on beamline B21 at Diamond (Didcot, UK) and on ID02 
(ESRF, France). 
At B21, solutions were loaded into the 96 well plate of an EMBL BioSAXS robot, and 
then injected via an automated sample exchanger into a quartz capillary (1.8 mm 
internal diameter) in the X-ray beam. The quartz capillary was enclosed in a vacuum 
chamber, in order to avoid parasitic scattering. After the sample was injected in the 
capillary and reached the X-ray beam, the flow was stopped during the SAXS data 
acquisition. B21 operated with a fixed camera length (3.9 m) and fixed energy (12.4 
keV).  The images were captured using a PILATUS 2M detector. Data processing was 
performed using dedicated beamline software Scatter.  
At ID02, samples were loaded in a glass capillary with a 2 mm internal radius.  The 
beamline operated at 12.46 keV energy with a flux of 2.19x1012 photon s-1 (100 mA). 
The sample-detector distance was 1474.2 mm. The 2D data was collected using 
a  Rayonix MX17038 detector, with a 2x2 binning, and processed using SAXSUtilities 
software.  
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Results 
We investigated the conformation and aggregation of PYY3-36 and derivatives of PYY3-
36 shown in Scheme 1. We first used the software PEPfold3
39-40 to compute the 
predicted conformation of PYY3-36 in comparison to a published solution NMR 
structure.12 PEPfold3 provides de novo conformational analysis based on a structural 
alphabet analysis which considers a peptide in sequence of four residues overlapping 
by three residues and compares the conformation with sequences generated by position-
specific iterative BLAST analysis using Uniprot protein database, followed by 
sterically allowed generation of progressively extended peptide conformations.39-40 
Scheme 2b shows an overlay of a PEPfold3 predicted structure with one of the 
ensemble of NMR conformers. There is a good degree of conformity in predicted and 
experimental structures, although the predicted -helical domain is shifted slightly 
from the NMR conformation (and is slightly longer). This is also confirmed by the local 
conformational analysis shown in Scheme 2c, which shows a predominance of -
helical structure from S(13) to L(30) (due to the structural alphabet overlap analysis, 
the conformation of the last two residues is not computed). For comparison, the 
software PSIPRED, based on the position specific scoring matrices generated by PSI-
BLAST, predicts that residues from P(14) to V(31) are in -helical conformation.41-42  
This combination of experimental and theoretical evidence indicates that substitutions 
at L(17) or Y(21) in PYY3-36 correspond to substitutions in the N-terminal region of the 
-helical domain or its centre. We then proceed to investigate the conformation and 
aggregation tendencies of K(17) and K(21) derivatives bearing octyl lipids or short PEG 
chains. These molecules have been prepared to enhance the biostability of  PYY3-36  
with possible therapeutic applications as discussed above.10  
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 We compare the conformational behaviour and self-assembly properties of derivatives 
of PYY which have been PEGylated by attachment of PEG [poly(ethylene glycol)] at 
K17 or K21 (K17-PEG22, K21-PEG22; Scheme 1a) or lipidated via attachment of an octyl 
chain at K17 or K21 (K17-Eoct, K21-Eoct; Scheme 1a).   
The self-assembly of PYY3-36 in water has recently been investigated.
10 Here, results on 
the self-assembly of PYY3-36 in water (Figure 1) will be used as a reference for the 
PYY3-36 conjugates.  
We first used a fluorescence dye probe to detect any critical concentration for 
aggregation or formation of hydrophobic pockets. The fluorescence of the dye ANS can 
be used to detect the cac as exemplified by our recent use of this method to detect cac 
values for several lipopeptides.43-44 ANS fluorescence assays are also frequently used 
to determine the formation of hydrophobic pockets during protein folding.31  
Figure S1 shows the dependence of I/Io as a function of log (c), together with the 
dependence of the same normalized intensity on c (inset Figure S1), measured for 
PYY3-36. The discontinuity in I/Io observed in the log(c) plot (Figure S1) is when the 
data is plotted on a linear concentration scale (inset Figure S1). Therefore, the ANS 
fluorescence assay does not show evidence for a self-assembly process driven by 
hydrophobic aggregation.  
An alternative fluorescence assay, which uses ThT and is sensitive to the formation of 
amyloid fibrils, was used to determine the cac of PYY3-36. Figure 1a displays the results 
obtained from the ThT assay. A cac value ~ 0.09 wt% PYY3-36 can be obtained from 
the discontinuity in fluorescence intensity. This discontinuity is visible in the 
dependence of I/Io with c (inset Figure 1a) or with log (c) (Figure 1a). This suggests that 
PYY3-36 forms amyloid structures above a critical concentration.  
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Cryo-TEM images reveal the self-assembly of long fibres (44.3±5) Å in diameter in a 
solution containing 1 wt% PYY3-36. It has been reported that the self-assembly PYY3-
36 depends on the pH of the solution for 2≤ pH ≤8.10 Here, 1 wt% PYY3-36 in water has 
pH 3, and fibres similar to those displayed in Figure 1b were previously found for 0.5 
wt% PYY3-36 at pH 2 and 4.
10  
Since the fibril formation leads to a ThT fluorescence response, characteristic of 
amyloids we also investigated UV absorbance of the Congo red dye which is another 
diagnostic of amyloid formation.45 The expected green shift of the absorbance 
maximum was not observed. In fact, this phenomenon was observed previously for an 
-helical peptide (apolipoprotein A-I fragments) forming fibrils (as shown by TEM).46 
Along with our results, this suggests that fibril-forming -helical peptides do not show 
all of the typical amyloid diagnostics, which is not surprising since the mode of binding 
of fluorescent dyes to -helical structures will differ from that of -sheet structures, for 
which binding occurs in the grooves of the -sheet fibrils.47-49 
CD was used to study the secondary structure of the fibres in Figure 1b. The CD 
spectrum (Figure S2) displays two minima (208 and 219 nm) and one maxima (189 
nm), corresponding to an -helical secondary structure.50 Equations 3-4 together with 
the spectrum in Figure S2 were used to calculate f= 20% and the ratio []222/[]208= 
0.9, which might indicate that the fibres are not made of coiled-coil aggregates of -
helices.25, 37  
Figure 1c shows the CD signal for samples containing 8.6x10-3 to 0.24 wt% PYY3-36, 
which ranges across the cac determined by ThT fluorescence assays (Figure 1a). The 
relative intensity as well as the absolute value of the ellipticity at = 208 and 222 nm 
changes with concentration, implying structural changes in the -helix conformation 
and coiled coil association. CD spectra in Figure 1c were used to calculate the helix 
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contents (𝑓; Equations 3-4) and the ratio of mean residual ellipticities at 222 and 208 
nm ([]222/[]208), which is a probe for the presence of coiled coil structures.37 
 Figure 1d displays the results calculated for 𝑓 and []222/[]208 as a function of  PYY3-
36 concentration.  
The analysis of the CD spectra provides low values of helical content (18≤ 𝑓 ≤ 14, 
Figure 1d) because the -helices comprise only 16 residues out of the total 34 residues 
in the peptide sequence (Scheme 1b).  It has been reported that values []222/[]208 ~ 1 
or higher indicate the formation of coiled coil aggregates of -helices.25, 37  
A steady decrease of []222/[]208 from 1.02—1.07 to 0.87—0.93, has been previously 
reported for synthetic peptides, and ascribed to the transition from two-stranded -
helical coiled coils to single-stranded -helices.37, 51-54 
Figure 1d shows that upon increasing concentration, []222/[]208 decreases from ~1.1 
to  ~0.95  above 0.05 wt% PYY3-36. This suggests that coiled coils are present at low 
concentration, but that these are disrupted above the cac (where []222/[]208 adopts a 
constant value ~0.95). The coiled coils present at low concentration are likely to be 
dimers when considering the likely pairwise facial aggregation (Scheme 1c). The loss 
of coiled coil structure at the cac is associated with the observation of fibrillar structures 
in the cryo-TEM image. However, the CD shows that the conformation is still -helical, 
i.e. these fibrils are formed by aggregation of helical PYY3-36 monomers. The 
observation of fibrils by a-helical peptides is rare (typically fibrils are associated with 
-sheet assembly). It is possible to design -helices to form fibrils by incorporating 
“sticky ends”,55 in particular sequences with oppositely charged termini. Actually, 
inspection of the full PYY3-36 sequence (Scheme 1) shows a preponderance of E and D 
residues at the N terminus and several R residues near the C terminus so this is a 
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possible origin of sticky ended coil aggregation into fibrils. It is notable that this 
requires consideration of the full peptide sequence and not just the core helical domain 
(Scheme 1c) in which there is no obvious pattern of charged residues. 
The PYY3-36 -helical structure steadily unfolds upon heating the sample from 10 to 
80oC (Figure 1e). The smooth decrease of 𝑓 with increasing T (inset Figure 1e) reveals 
a cooperative unfolding. This structural change is also reversible, since PYY3-36 folds 
back to its original structure when the temperature is decreased from 80 to 20oC (Figure 
1f).  
Having discussed the conformation and self-assembly of PYY3-36 itself, we compared 
it with the conformational behaviour and self-assembly of K17-PEG22, K21-PEG22, K17-
Eoct and K21-Eoct (Scheme 1a).   
ANS emission fluorescence spectra for solutions containing K17-Eoct, K21-Eoct, K17-
PEG22 and K21-PEG22 were characterized by a single maximum, which showed a 
simultaneous blue shift and intensity enhancement upon increasing concentration of 
peptide. A representative example is displayed in Figure S3 for K17-Eoct. Plots of I/Io 
vs c for the peptide conjugates are displayed in Figure S4. 
The ANS fluorescence blue shift and intensity enhancement results from ion pair 
formation between the sulfonate group of ANS and the charged group of Arg residues, 
when the probe is hosted in a non-polar environment.31, 43, 56-59  Here, the Arg residues  
are in the -helix region and the C-termini of the PYY3-36 backbone (Scheme 1b).10 As 
a consequence, higher values of I/Io are due to stronger binding between ANS and the 
Arg groups in a non-polar environment. This effect can explain the trend displayed in 
Figures S4 and S1:  I/Io(K21-EOct) > I/Io(K17-EOct)  > I/Io(K21-PEG22)  > I/Io K17-
PEG22), all values also being higher than I/Io(PYY3-36). Clearly, lipidation or 
PEGylation of PYY3-36 influences the binding affinity of ANS.  
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While I/Io vs c can be fitted with a straight line for K17-PEG22 and K21-PEG22 (Figures 
S4a-b), it has a sigmoidal growth, associated to a hydrophobic collapse, for K17-Eoct 
and K21-Eoct (Figures S4c-d). As discussed in the paragraph above, K17-Eoct and K21-
Eoct also show the highest I/Io ratios. 
Figure 2 shows the presence of a cac~ 0.03 wt% for K17-Eoct and K21-Eoct, as 
determined from the I/Io vs log(c) plots. The hydrophobic collapse of K17-Eoct and K21-
Eoct indicates the self-assembly of nanostructures different from PYY3-36 fibres, as will 
be discussed later in the manuscript.  
CD was used to study changes in the secondary structure of K17-Eoct, K21-Eoct, K17-
PEG22 and K21-PEG22 as a function of concentration, in the range 4.3x10
-2 wt%-0.08 
wt% conjugated peptide. The spectra in Figure 3 show the characteristics of an -helical 
secondary structure.50 The CD spectra in Figure 3 were used to calculate 𝑓 and 
[]222/[]208. The results are displayed in Figure 4 as a function of the sample 
concentration, which shows that 𝑓 decreases substantially with concentration for K17-
Eoct and K21-Eoct and K17-PEG22 (Figure 4a, c-d).  This situation is reversed for K21-
PEG22, which reaches higher and stable values of 𝑓 at higher concentration (Figure 4b). 
The explanation for this is not completely clear, but it may to be due to the increased 
presence of small aggregates (dimers and tetramers) revealed uniquely for this sample 
by AUC (to be discussed shortly). As a whole, 𝑓 values are at least two times higher 
in Figure 4 than in Figure 1d. Thus, PEGylation or lipidation of PYY3-36 unexpectedly 
promotes -helical formation.  
As mentioned above, values []222/[]208 ~1 or higher indicate the formation of coiled 
coil aggregates of -helices whereas significantly lower values are characteristic of 
single stranded -helices. 34, 49-52  
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Measured values for []222/[]208 show that none of the PEGylated conjugates form 
coiled coil structures.  In fact, the maximum value []222/[]208~ 0.87, for K21-PEG22 
corresponds to single -helical helices (Figure 4b). 
For K17-Eoct and K21-Eoct []222/[]208 changes from 1.05-1.01 to 0.82-0.78 with 
increasing concentration and the decrease occurs at the cac (Figures 4c-d). As for the 
PEGylated peptides, Figures 4c-d suggest the presence of mostly single -helix-
containing peptide structures, even above the cac, for the lipidated peptides. This is in 
good agreement with the tendency for aggregate formation through hydrophobic 
collapse, as described shown by the ANS results discussed above. 
The temperature dependence of conformation was studied using CD spectroscopy for 
the lipidated and PEGylated derivatives. Figure 5a displays representative results 
obtained for the dependence of the CD signal on the temperature measured for 0.08 
wt% K21-PEG22. The dependence of the CD spectra with temperature for K17-Eoct, K21-
Eoct and K17-PEG22 (Figure S5), was used together with the data in Figure 5a to 
calculate 𝑓 values plotted in Figure 5b. Increasing the temperature from 20 
oC to 80 oC 
causes a great loss of -helix content for all the peptides, but refolding of the -helix 
is observed when the temperature is reduced from 80oC to 20oC, i.e. the temperature-
induced conformational change is thermo-reversible (Figure 5c).   
The observation that 𝑓 decreases markedly with temperature for all four peptide 
conjugates, including the two PEGylated peptides is consistent with previous work that 
showed that attachment of PEG chains to short model -helical peptides does not 
stabilize them against reduction in coiled coil content as temperature is increased.25 A  
dramatic decrease of helical content with increasing temperature was also recorded by 
CD for palmitoyl- conjugated PYY3-36 aqueous solutions.
10  
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Analytical ultracentrifugation experiments were performed at 0.01, 0.05 and 0.1 wt% 
peptide conjugate to complement the CD and fluorescence probe measurements.  Table 
S1 contains the estimated molecular weights from the c(s) analysis. Figures 6a-f present 
the sedimentation coefficient distributions obtained for these samples from the 
absorbance (Figures 6a,c) or  interference (Figures 6b,d-f) measurement. 
The molecular weight Mw of the conjugated peptides listed in Table S1 is calculated 
through the c(s) analysis and therefore depends on the frictional ratio parameter (f/f0). 
The frictional ratio is fit globally during the analysis. Therefore, if there is more than 
one species present, the calculated f/f0 is an average value for all the species. 
Consequently, Mw calculated using an average f/f0 (Table S1) corresponds to a 
molecular weight averaged over all the species in the system. 
The results for K17-PEG22 and K21-PEG22 are very similar (Figures 6a-d, Table S1). 
Results present evidence of non-ideality, probably caused by unusual molecular shapes. 
This manifests as a concentration dependent effect whereby the sedimentation 
coefficient and molecular weight of a species both get smaller with increasing sample 
concentration.  
Solutions of K17-PEG22 and K21-PEG22 are dominated by species with a molecular 
weight consistent with that of a monomer in 0.01-0.1 wt% solutions of PEGylated 
conjugate (peak 1, Figure 6a-d and Table S1). The AUC data for K17-PEG22 also 
indicates a likely equilibrium involving a population of dimeric and tetrameric coiled 
coils as well as monomer in 0.01-0.1 wt% solutions (peak 2, Figure 6a-d and Table S1). 
The K21-PEG22 samples contain a significant population of species that are most likely 
dimers and tetramers (peaks 2 and 3, Figure 6a-d and Table S1). The relative proportion 
of these is given in Table S1. The K21-PEG22 sample also contains a small proportion 
of some lower molecular weight species that could result from sample degradation.  
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The results for K17-Eoct and K21-Eoct are very similar (Figure 6e-f, Table S1). Both 
appear as predominantly a single non-ideal species (peak 1). Given the apparent 
molecular weight, the predominant species for K17-Eoct and K21-Eoct is likely to be 
monomer for the solutions with 0.01-0.1 wt% lipidated peptide. There is also evidence 
of a small amount of larger species in both samples at 0.05 and 0.1 wt% K17-Eoct and 
0.01-0.1 wt% K21-Eoct (peak 2, Figure 6e-f, Table S1). This is likely to indicate the 
presence of aggregates since the cac is estimated to be 0.03 wt% according to ANS 
fluorescence probe studies (Figure 2) The molecular weights listed for peak 2 (K17-Eoct 
and K21-Eoct samples, Table S1) indicate that the apparent association number (p) of 
these oligomeric clusters is in the range 5-10. This result actually agrees with the value 
(p = 7) estimated for micelles made of PYY3-36 lipidated at positions 11 or 23 with a 
palmitoyl chain at pH 2 and 4 reported by us in a previous study of PYY3-36 
conjugates.10 
The self-assembly of the peptide conjugates in solution was investigated using SAXS 
at 0.5 wt% peptide conjugate. The corresponding SAXS curves are displayed in Figure 
7. The shape of the SAXS curves for the PEGylated peptides is different from the shape 
of the SAXS curves for the lipidated peptides. The SAXS data for K17-PEG22 and K21-
PEG22   (Figure 7a) was fitted using the form factor of a Gaussian coil, while the SAXS 
data for K17-Eoct and K21-Eoct (Figure 7b) was fitted using a spherical core and shell 
form factor, consistent with the presence of spherical micelles. These models provide 
excellent representations of the SAXS intensity profiles. The parameters obtained from 
the SAXS fittings are listed in Table S2.  
The fitting of the SAXS data for PEGylated peptides describes the structure of a 
solution rich in oligomeric species (Figure 7a).  The radius of gyration of PEG with a 
molar mass of 22,000 g mol-1 is estimated to be Rg = 51 Å, which is close to Rg = 50 Å 
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obtained from the fitting of the SAXS data for 0.5 wt% K21-PEG22 in Figure 7a (Table 
S2). Therefore, SAXS indicates the existence of monomers or small oligomers in 0.5 
and 1 wt% solutions of K21-PEG22 (SAXS data not shown for 1 wt% sample). On the 
other hand, Rg = 130 Å obtained for 0.5 wt% K17-PEG22 (Table S2) suggests the 
formation of oligomers in solution. The excluded volume parameter 0.4 and 0.57 
for K17-PEG22 and K21-PEG22 respectively shows that the PEG chain is more swollen 
for the K17-PEG22 oligomer than for the K21-PEG22 monomer. 
The fitting of the SAXS data for lipidated peptides indicates the formation of micelles 
with a well-defined core- shell structure. According to this model, K17-Eoct and K21-
Eoct micelles have an external polydisperse radius R1 = (20±5.5) Å and  (19.5±5.5) Å 
respectively (Table S2). The internal micellar core radius is R2 = 7 Å and 9.2 Å for K17-
Eoct and K21-Eoct respectively (Table S2).  
Based on the analysis of CD, AUC and SAXS data, at low concentration PEGylated 
conjugates are present as populations of dimeric and tetrameric coiled coil structures, 
along with a large population of monomers. In contrast, lipidated peptides form 
micelles for concentrations equal or higher than 0.5 wt%.  
Cryo-TEM experiments were carried out on samples containing 2 wt% conjugated 
peptides, in order to obtain images of the self-assembled nanostructure. We did not 
observe discrete nanostructures in any cryo-TEM images for the PEGylated peptides. 
This is consistent with the presence of monomers and only small oligomers. In contrast, 
cryo-TEM images for the lipidated peptides show the formation of micelles ~35-45 Å 
in diameter (Figure 8a-b). Along with the molecular volume, estimated to be 4901 Å3 
for PYY3-36, estimated based on residue specific partial volumes
60 (which will not be 
significantly modified by attachment of one side octyl chain) and the estimate micelle 
radius estimated from SAXS (20 Å), the association number of the lipidated peptide 
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aggregates is found to be approximately p = 7. This corresponds to small oligomeric 
structures and differs from the typical association numbers (several tens or even 
hundreds) for surfactant micelles.61-62 This value is in good agreement with AUC results 
which indicate the formation of small oligomers containing 5-10 molecules for the two 
lipidated peptides (Table S1) and with a previous report on micelles formed by 
palmitoylated PYY3-36 derivatives.
10  
In summary, cryo-TEM results are in good agreement with AUC and SAXS results 
discussed above indicating the absence of large aggregate structures for K17-PEG22 and 
K21-PEG22 and the self-assembly of spherical micelles ~40 Å in diameter for K17-Eoct 
and K21-Eoct. 
 
 
Conclusions 
We have compared the conformation and self-assembly behaviours of lipidated and 
PEGylated derivatives of peptide hormone human PYY3-36, which has a C-terminal -
helical domain. The influence of solution concentration on the conformation and self-
assembly has been examined. The effect of lipidation and PEGylation in stabilizing -
helical conformation against changes in temperature has been probed. 
CD spectra confirm the presence of -helical content for PYY3-36 at low concentration, 
with a significant degree of coiled coil formation at low concentration. However at 
sufficiently high concentration (above the cac determined through ThT fluorescence 
measurements) cryo-TEM reveals fibril structures with an -helical secondary 
structure. The peptide is not stable against heating and the -helical conformation is 
lost upon heating to 80 oC in a “denaturing process”. However, this is fully reversible 
as shown by the recovery of the CD spectrum at 20 oC. The formation of fibrils by -
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helical PYY3-36 is noteworthy. Although these may not be typical amyloid fibrils (since 
Congo red binding is not observed), it may be noted that several classes of peptide 
hormone form amyloid structures which are useful storage depots,63-64 regulating their 
activity in vivo. Whether PYY3-36 forms “amyloid” (or at least fibril structures) under 
physiological conditions is a subject for future investigation, however it may be noted 
that it was observed to form amyloid in acidic aqueous conditions (without 
physiological buffers).10 Potential concentration-dependent self-assembly of lipidated 
and PEGylated PYY3-36 derivatives was assayed via ANS fluorescence measurements. 
This indicated that the two lipidated derivatives show a critical aggregation 
concentration whereas the two PEGylated peptides do not show aggregation behaviour. 
CD spectra indicate that surprisingly both lipidated and PEGylated conjugates have 
significantly higher -helix content than the native PYY3-36 peptide. In addition, CD 
shows that the PEGylated peptides form monomers and only small oligomers, which is 
consistent with the PEG forming a steric barrier around isolated peptides, thus 
preventing their association. SAXS also shows that solutions of the PEGylated peptides 
are dominated by monomers and oligomeric structures, with a radius of gyration 
comparable to that of 22,000 g mol-1 PEG chains. However, AUC indicates the presence 
of a fraction of, especially, dimeric aggregates, in particular for K21-PEG22. This 
conjugate shows a unique concentration-dependent increase in -helical content, in 
contrast to all other peptides studied. This highlights the importance of the site of 
PEGylation. PEGylation at residue 21 corresponds to loss of the negative charge of the 
lysine residue in the native peptide sequence whereas PEGylation at residue 17 
corresponds to replacement of hydrophobic leucine with the PEGylated residue 
(leading to enhanced peptide solubility). The CD spectra show that PEGylation (at 
either position 17 or 21) enhances the thermal stability of the peptide, because there is 
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a much reduced change in -helix conformation with temperature compared to the 
native peptide (and also reduced concentration dependence).  
The behaviour of the two lipidated peptides is quite distinct from that of the two 
PEGylated derivatives, or that of PYY3-36 itself. Fluorescence assays using ANS show 
a critical aggregation process associated with hydrophobic collapse. The cac is also 
evident in plots of the concentration-dependent -helix content obtained from CD 
spectra (or coiled coil content which tracks -helix content). Cryo-TEM shows the 
presence of well-defined micelles with a diameter of 4 nm. AUC also indicates a 
population of aggregate structures with a low degree of association. This is consistent 
with the estimated aggregation number (p = 7) from the observed micelle volume 
divided by molecular volume. These structures are oligomeric species rather than 
conventional surfactant-like micelles which typically have a much larger association 
number.61-62 The small size of the alkyl chains relative to the hydrophilic peptide “head 
groups” does not permit close packing in micelles with a large association number 
which are observed for conventional amphiphiles where the hydrophilic moiety is much 
smaller (smaller than the lipid chain or comparable to it). CD shows that lipidation does 
not improve thermal stability of -helix conformation to the same extent as PEGylation.  
Our results show that PEGylation and lipidation are potentially valuable strategies to 
tune the conformation of peptide hormones, in particular to enhance their 
thermostability.  PEGylation reduces coiled coil aggregation whereas lipidation leads 
to the formation of small oligomeric structures above a critical aggregation 
concentration. These findings may benefit the development of future therapeutics based 
on PYY3-36. 
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Figures and Schemes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. (a) Molecular Structures of the derivatives studied. Residues L(17)  or Y(21) 
are substituted with lysine derivatives with octyl lipid chains or short PEG chains 
attached via -glutamic acid linkers. (b) PYY3-36 with residues in the -helical domain, 
determined by solution NMR studies,7,8 highlighted in red. (c) Helical wheel 
representation of PYY3-36 (generated using http://rzlab.ucr.edm 
/scripts/wheel/wheel.cgi,). The hydrophilic residues are represented as circles, 
hydrophobic residues as diamonds, and potentially positively charged as pentagons. 
Hydrophobicity is colour coded: the most hydrophobic residue is green, and the amount 
of green decreases proportionally to the hydrophobicity, with zero hydrophobicity 
coded as yellow. The potentially charged residues are light blue. Hydrophilic residues 
are coded red with pure red being the most hydrophilic (uncharged) residue, and the 
amount of red decreasing proportionally to the hydrophilicity. The boxes indicate sites 
of lipidation or PEGylation with the residues indicated replaced as shown in (a).   
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Scheme 2.  (a) Ensemble of conformations from solution NMR (pdb file: 2dez) of 
human PYY(3-36).12 (b) Overlay of experimental (green) and PEPfold3 predicted 
(cyan) structures (in each case the first model from the ensemble is taken for 
convenience).  (c) The predicted local structure analysis. Red is helical, blue is coil 
(disordered) and green is ‘extended’. Obtained using PEPfold3.39-40 
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Figure 1. PYY3-36 in solution: (a) ThT  fluorescence assay; (b) cryo-TEM image; (c) 
concentration dependence of the CD signal; (d)  𝑓 and []222/[]208 calculated from (c); 
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(e) temperature dependence of the CD signal (inset displays calculated 𝑓) and (f) 
thermal reversibility of the PYY3-36 helix unfolding, probed by CD. 
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Figure 2. Fluorescence intensity (I) normalized to that of ANS in aqueous solution 
(I0) at the emission wavelength em, plotted as a function of the lipidated peptide 
concentration c: (a) K17-Eoct, (b) K21-Eoct.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Concentration-dependent circular dichroism spectra  (a) K17-PEG22, (b) K21-
PEG22, (c) K17-EOct and  (d) K21-EOct. 
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Figure 4. Concentration-dependent conformational analysis of circular dichroism 
spectra – f denotes helix content and the ratio []222/[]208 is a measure of coiled coil 
content, both calculated from the data plotted in Figure 3.  (a) K17-PEG22, (b) K21-
PEG22, (c) K17-EOct and (d) K21-EOct.  
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Figure 5. (a) Temperature-dependent CD spectra for 0.08 wt% K21-PEG22, (b) 
dependence of 𝑓 on the temperature, calculated from the CD spectra for all the peptide 
conjugates, (c) Showing thermoreversibility of CD spectra for K21-PEG22. 
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Figure 6. Sedimentation coefficient distributions. (a,c) Absorbance data. (b,d-f)  
Interference data. 
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Figure 7. SAXS data measured for 0.5 wt% of (a) K17-PEG22 and K21-PEG22 and (b)  
K17-Eoct and K21-Eoct. The full lines are the fitting top the data. The SAXS curves have 
been multiplied by an arbitrary factor in order to aid visualisation. 
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Figure 8. Cryo-TEM images for 2 wt% solutions of (a) K17-Eoct and (b) K21-Eoct  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
References 
1. Hutchinson, J. A.; Burholt, S.; Hamley, I. W., Peptide hormones and 
lipopeptides: from self-assembly to therapeutic applications. J. Peptide Sci. 2017, 
23 (2), 82-94. 
2. Huda, M. S. B.; Wilding, J. P. H.; Pinkney, J. H., Gut peptides and the regulation 
of appetite. Obes. Rev. 2006, 7 (2), 163-182. 
3. Hazelwood, R. L., The pancreatic-polypeptide (PP-fold) family - gastrointestinal, 
vascular, and feeding behavioral-implications. Proc. Soc. Exp. Biol. Med. 1993, 
202 (1), 44-63. 
4. Moran, T. H., Pancreatic polypeptide: More than just another gut hormone? 
Gastroenterology 2003, 124 (5), 1542-1544. 
5. Ehrlich, G. K.; Michel, H.; Truitt, T.; Riboulet, W.; Pop-Damkov, P.; Goelzer, P.; 
Hainzl, D.; Qureshi, F.; Lueckel, B.; Danho, W.; Conde-Knape, K.; Konkar, A., 
Preparation and characterization of albumin conjugates of a truncated Peptide YY 
analogue for half-life extension. Bioconjugate Chem. 2013, 24 (12), 2015-2024. 
6. Keire, D. A.; Bowers, C. W.; Solomon, T. E.; Reeve, J. R., Structure and receptor 
binding of PYY analogs. Peptides 2002, 23 (2), 305-321. 
7. Keire, D. A.; Mannon, P.; Kobayashi, M.; Walsh, J. H.; Solomon, T. E.; Reeve, J. 
R., Primary structures of PYY, Pro34 PYY, and PYY-(3-36) confer different 
conformations and receptor selectivity. Am. J. Physiol.-Gastroint. Liver Physiol. 
2000, 279 (1), G126-G131. 
8. Keire, D. A.; Kobayashi, M.; Solomon, T. E.; Reeve, J. R., Solution structure of 
monomeric peptide YY supports the functional significance of the PP-fold. 
Biochemistry 2000, 39 (32), 9935-9942. 
36 
 
9. Shechter, Y.; Tsubery, H.; Mironchik, M.; Rubinstein, M.; Fridkin, M., 
Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake 
in mice. FEBS Letters 2005, 579 (11), 2439-2444. 
10. Hutchinson, J. A.; Burholt, S.; Hamley, I. W.; Lundback, A. K.; Uddin, S.; dos 
Santos, A. G.; Reza, M.; Seitsonen, J.; Ruokolainen, J., The effect of lipidation 
on the self-assembly of the gut-derived peptide hormone PYY3-36. Bioconjugate 
Chem. 2018, 29, 2296-2308. 
11. Beck-Sickinger, A. G.; Wieland, H. A.; Wittneben, H.; Willim, K. D.; Rudolf, K.; 
Jung, G., Complete L-alanine scan of neuropeptide-Y reveals ligands binding to 
Y1 and Y2 receptors with distinguished conformations. Eur. J. Biochem. 1994, 
225 (3), 947-958. 
12. Nygaard, R.; Nielbo, S.; Schwartz, T. W.; Poulsen, F. M., The PP-fold solution 
structure of human polypeptide YY and human PYY3-36 as determined by NMR. 
Biochemistry 2006, 45 (27), 8350-8357. 
13. Henry, K. E.; Elfers, C. T.; Burke, R. M.; Chepurny, O. G.; Holz, G. G.; Blevins, 
J. E.; Roth, C. L.; Doyle, R. P., Vitamin B-12 Conjugation of Peptide-YY3-36 
Decreases Food Intake Compared to Native Peptide-YY3-36 Upon Subcutaneous 
Administration in Male Rats. Endocrinology 2015, 156 (5), 1739-1749. 
14. Henry, K. E.; Kerwood, D. J.; Allis, D. G.; Workinger, J. L.; Bonaccorso, R. L.; 
Holz, G. G.; Roth, C. L.; Zubieta, J.; Doyle, R. P., Solution Structure and 
Constrained Molecular Dynamics Study of Vitamin B-12 Conjugates of the 
Anorectic Peptide PYY(3-36). ChemMedChem 2016, 11 (9), 1015-1021. 
15. Zapadka, K. L.; Becher, F. J.; dos Santos, A. L. G.; Jackson, S. E., Factors 
affecting the physical stability (aggregation) of peptide therapeutics. Interface 
Focus 2017, 7 (6), 18. 
37 
 
16. Erak, M.; Bellmann-Sickert, K.; Els-Heindl, S.; Beck-Sickinger, A. G., Peptide 
chemistry toolbox - Transforming natural peptides into peptide therapeutics. 
Bioorg. Med. Chem. 2018. 
17. Delgado, C.; Francis, G. E.; Fisher, D., Crit. Rev. Therapeutic Drug Carrier Syst. 
1992, 9 (3,4), 249-304. 
18. Duncan, R., The dawning era of polymer therapeutics. Nature Rev. Drug 
Discovery 2003, 2 (5), 347-360. 
19. Ryan, S. M.; Mantovani, G.; Wang, X.; Haddleton, D. M.; Brayden, D. J., 
Advances in PEGylation of important biotech molecules: delivery aspects. Expert 
Opin. Drug Deliv. 2008, 5, 371-383. 
20. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S., Poly(ethylene glycol) in 
drug delivery: Pros and cons as well as potential alternatives. Angew. Chem. Int. 
Ed. Engl. 2010, 49 (36), 6288-6308. 
21. Alconcel, S. N. S.; Baas, A. S.; Maynard, H. D., FDA-approved poly(ethylene 
glycol)-protein conjugate drugs. Polym. Chem. 2011, 2 (7), 1442-1448. 
22. Hamley, I. W., PEG-Peptide Conjugates. Biomacromolecules 2014, 15 (5), 1543-
1559. 
23. Hamley, I. W.; Castelletto, V., Self-Assembly of peptide bioconjugates: Selected 
recent research highlights. Bioconjugate Chem. 2017, 28 (3), 731-739. 
24. Thieme, V.; Jolly, N.; Madsen, A. N.; Bellmann-Sickert, K.; Schwartz, T. W.; 
Holst, B.; Cox, H. M.; Beck-Sickinger, A. G., High molecular weight PEGylation 
of human pancreatic polypeptide at position 22 improves stability and reduces 
food intake in mice. Br. J. Pharmacol. 2016, 173 (22), 3208-3221. 
25. Vandermeulen, G.; Tziatzios, C.; Klok, H., Reversible self-organization of 
poly(ethylene glycol)-based hybrid block copolymers mediated by a de novo 
38 
 
four-stranded alpha-helical coiled coil motif Macromolecules 2003, 36, 4107-
4114  
26. Klok, H. A.; Vandermeulen, G. W. M.; Nuhn, H.; Rosler, A.; Hamley, I. W.; 
Castelletto, V.; Xu, H.; Sheiko, S. S., Peptide mediated formation of 
hierarchically organized solution and solid state polymer nanostructures. Faraday 
Discuss. 2005, 128, 29-41. 
27. Yu, Y. C.; Berndt, P.; Tirrell, M.; Fields, G. B., Self-assembling amphiphiles for 
construction of protein molecular architecture. J. Am. Chem. Soc. 1996, 118 (50), 
12515-12520. 
28. Hamley, I. W., Lipopeptides: from self-assembly to bioactivity. Chem. Comm. 
2015, 51 (41), 8574-8583. 
29. Bellmann-Sickert, K.; Elling, C. E.; Madsen, A. N.; Little, P. B.; Lundgren, K.; 
Gerlach, L. O.; Bergmann, R.; Holst, B.; Schwartz, T. W.; Beck-Sickinger, A. G., 
Long-acting lipidated analogue of human pancreatic polypeptide is slowly 
released into circulation. J. Med. Chem. 2011, 54 (8), 2658-2667. 
30. Made, V.; Babilon, S.; Jolly, N.; Wanka, L.; Bellmann-Sickert, K.; Gimenez, L. 
E. D.; Morl, K.; Cox, H. M.; Gurevich, V. V.; Beck-Sickinger, A. G., Peptide 
modifications differentially alter G Protein-Coupled Receptor internalization and 
signaling Bias. Angew. Chem. Int. Ed. Engl. 2014, 53 (38), 10067-10071. 
31. Hawe, A.; Sutter, M.; Jiskoot, W., Extrinsic fluorescent dyes as tools for protein 
characterization. Pharm. Res. 2008, 25 (7), 1487-1499. 
32. LeVine, H., Thioflavine-T interaction with synthetic Alzheimers-disease beta-
amyloid peptides- detection of amyloid aggregation in solution. Protein Science 
1993, 2, 404-410. 
39 
 
33. LeVine, H., Quantification of -sheet amyloid fibril structures with thioflavin T. . 
In Methods in Enzymology, Wetzel, R., Ed. Academic Press: San Diego, 1999; 
Vol. 309, pp 274-284. 
34. Cohen, J. A.; Podgornik, R.; Hansen, P. L.; Parsegian, V. A., A 
Phenomenological one-parameter equation of state for osmotic pressures of PEG 
and other neutral flexible polymers in good solvents. J. Phys. Chem. B 2009, 113 
(12), 3709-3714. 
35. Durchschlag, H.; Zipper, P., Calculation of partial specific volumes and other 
volumetric properties of small molecules and polymers. J. Appl. Cryst. 1997, 30 
(2), 803-807. 
36. Schuck, P., Size-distribution analysis of macromolecules by sedimentation 
velocity ultracentrifugation and Lamm equation modeling. Biophys. J. 2000, 78 
(3), 1606-1619. 
37. Su, J. Y.; Hodges, R. S.; Kay, C. M., Effect of chain-length on the formation and 
stability of synthetic alpha-helical coiled coils. Biochemistry 1994, 33 (51), 
15501-15510. 
38. Van Vaerenbergh, P.; Leonardon, J.; Sztucki, M.; Boesecke, P.; Gorini, J.; 
Claustre, L.; Sever, F.; Morse, J.; Narayanan, T., An upgrade beamline for 
combined wide, small and ultra small-angle x-ray scattering at the ESRF. In 
Proceedings of the 12th International Conference on Synchrotron Radiation 
Instrumentation, Shen, Q.; Nelson, C., Eds. 2016; Vol. 1741. 
39. Maupetit, J.; Derreumaux, P.; Tuffery, P., A Fast Method for Large-Scale De 
Novo Peptide and Miniprotein Structure Prediction. J. Comput. Chem. 2010, 31 
(4), 726-738. 
40 
 
40. Shen, Y. M.; Maupetit, J.; Derreumaux, P.; Tuffery, P., Improved PEP-FOLD 
Approach for Peptide and Miniprotein Structure Prediction. J. Chem. Theory 
Comput. 2014, 10 (10), 4745-4758. 
41. Buchan, D. W. A.; Minneci, F.; Nugent, T. C. O.; Bryson, K.; Jones, D. T., 
Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic 
Acids Res. 2013, 41 (W1), W349-W357. 
42. Jones, D. T., Protein secondary structure prediction based on position-specific 
scoring matrices. J. Molec. Biol. 1999, 292 (2), 195-202. 
43. Castelletto, V.; Ryumin, P.; Cramer, R.; Hamley, I. W.; Taylor, M.; Allsop, D.; 
Reza, M.; Ruokolainen, J.; Arnold, T.; Hermida-Merino, D.; Garcia, C. I.; Leal, 
M. C.; Castaño, E., Self-assembly and anti-amyloid cytotoxicity activity of 
Amyloid beta peptide derivatives. Sci. Rep. 2017, 7, 12. 
44. Castelletto, V.; Kirkham, S.; Hamley, I. W.; Kowalczyk, R.; Rabe, M.; Reza, M.; 
Ruokolainen, J., self-assembly of the toll-like receptor agonist macrophage-
activating lipopeptide MALP-2 and of its constituent peptide Biomacromolecules 
2016, 17, 631-640. 
45. Hamley , I. W., Peptide fibrillization. Angew. Chem. Int. Ed. Engl. 2007, 46, 
8128-8147. 
46. Lazar, K. L.; Miller-Auer, H.; Getz, G. S.; Orgel, J.; Meredith, S. C., Helix-turn-
helix peptides that form alpha-helical fibrils: Turn sequences drive fibril 
structure. Biochemistry 2005, 44 (38), 12681-12689. 
47. Biancalana, M.; Koide, S., Molecular mechanism of Thioflavin-T binding to 
amyloid fibrils. Biochim. Biophys. Acta-Proteins and Proteomics 2010, 1804 (7), 
1405-1412. 
41 
 
48. Groenning, M., Binding mode of Thioflavin T and other molecular probes in the 
context of amyloid fibrils-current status. J. Chem. Biol. 2010, 3 (1), 1-18. 
49. Wu, C.; Wang, Z. X.; Lei, H. X.; Zhang, W.; Duan, Y., Dual binding modes of 
Congo red to amyloid protofibril surface observed in molecular dynamics 
simulations. J. Am. Chem. Soc. 2007, 129 (5), 1225-1232. 
50. Kelly, S. M.; Jess, T. J.; Price, N. C., How to study proteins by circular dichroism 
Biochim. Biophys. Acta- Proteins and Proteomics 2005, 1751, 119-139. 
51. Engel, M.; Williams, R. W.; Erickson, B. W., Designed coiled-coil proteins - 
synthesis and spectroscopy of two 78-residue -helical dimers. Biochemistry 
1991, 30 (13), 3161-3169. 
52. Lau, S. Y. M.; Taneja, A. K.; Hodges, R. S., Synthesis of a model protein of 
defined secondary and quaternary structure - Effect of chain-length on the 
stabilization and formation of 2-stranded alpha-helical coiled-coils. J. Biol. 
Chem. 1984, 259 (21), 3253-3261. 
53. Monera, O. D.; Zhou, N. E.; Kay, C. M.; Hodges, R. S., Comparison of 
Antiparallel and Parallel 2-Stranded Alpha-Helical Coiled-Coils - Design, 
Synthesis and Characterization. J. Biol. Chem. 1993, 268 (26), 19218-19227. 
54. Zhu, B. Y.; Zhou, N. E.; Semchuk, P. D.; Kay, C. M.; Hodges, R. S., Design, 
Synthesis and Structural Characterization of Model Heterodimeric Coiled-Coil 
Proteins. Int. J. Pept. Protein Res. 1992, 40 (3-4), 171-179. 
55. Woolfson, D. N., Building fibrous biomaterials from -helical and collagen-like 
coiled-coil peptides. Biopolymers 2010, 94 (1), 118-127. 
56. Gasymov, O. K.; Glasgow, B. J., ANS fluorescence: Potential to augment the 
identification of the external binding sites of proteins. Biochim. Biophys. Acta-
Proteins and Proteomics 2007, 1774 (3), 403-411. 
42 
 
57. Munishkina, L. A.; Fink, A. L., Fluorescence as a method to reveal structures and 
membrane-interactions of amyloidogenic proteins. Biochim. Biophys. Acta-
Biomembranes 2007, 1768 (8), 1862-1885. 
58. Poklar, N.; Lah, J.; Salobir, M.; Macek, P.; Vesnaver, G., pH and temperature-
induced molten globule-like denatured states of equinatoxin II: A study by UV-
melting, DSC, far- and near-UV CD spectroscopy, and ANS fluorescence. 
Biochemistry 1997, 36 (47), 14345-14352. 
59. Huttenhain, S. H.; Balzer, W., Solvatochromic Fluorescence of 8-(Phenylamino)-
1-Naphtalene-Ammoniumsulfonate (8,1 ANS) in 1,4-Dioxane Water Mixtures, 
Revisited. Z. Naturfors. Sect. A-J. Phys. Sci. 1993, 48 (5-6), 709-712. 
60. Buehler, E.; Cao, Q. Oligo Calc: Oligonucleotide Properties Calculator 
(http://biotools.nubic.northwestern.edu/OligoCalc.html), 1996-2001. 
61. Fennel Evans, D.; Wennerstrom, H., The colloidal domain. Where physics, 
chemistry and biology meet. New York, 1999. 
62. Hamley, I. W., Introduction to Soft Matter. John Wiley: Chichester, 2007. 
63. Maji, S. K.; Perrin, M. H.; Sawaya, M. R.; Jessberger, S.; Vadodaria, K.; 
Rissman, R. A.; Singru, P. S.; Nilsson, K. P. R.; Simon, R.; Schubert, D.; 
Eisenberg, D.; Rivier, J.; Sawchenko, P.; Vale, W.; Riek, R., Functional 
Amyloids As Natural Storage of Peptide Hormones in Pituitary Secretory 
Granules. Science 2009, 325 (5938), 328-332. 
64. Anoop, A.; Ranganathan, S.; Das Dhaked, B.; Jha, N. N.; Pratihar, S.; Ghosh, S.; 
Sahay, S.; Kumar, S.; Das, S.; Kombrabail, M.; Agarwal, K.; Jacob, R. S.; 
Singru, P.; Bhaumik, P.; Padinhateeri, R.; Kumar, A.; Maji, S. K., Elucidating the 
role of disulfide bond on amyloid formation and fibril reversibility of 
43 
 
Somatostatin-14. Relevance to its storage and secretion. J. Biol. Chem. 2014, 289 
(24), 16884-16903. 
 
  
44 
 
TOC Entry 
 
 
